Skip to main content

Daily Digest: DocuSign in acquisition crosshairs; Financial giant to cut 20K jobs

Meanwhile, Swiss drugmaker Novartis has backed away from its effort to acquire Cytokinetics, prompting the South San Francisco-based drug developer's shares to fall about 20% on Thursday.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.